<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369430</url>
  </required_header>
  <id_info>
    <org_study_id>AKST4290-211</org_study_id>
    <nct_id>NCT04369430</nct_id>
  </id_info>
  <brief_title>Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment</brief_title>
  <acronym>TEAL</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkahest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkahest, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's
      Disease who are currently on stable dopaminergic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in motor function during levodopa withdrawal.</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Change from Baseline in motor function during the practically defined off-medication state, defined as at least 12 hours off levodopa, at Week 12 as measured by Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part 3 Motor Examination (33 scores based on 18 questions with several right, left, or both body distribution scores). Each Parkinsonian sign or symptom is rated on a 5‐point Likert‐type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The minimum score on the MDS-UPDRS Part 3 is 0 and the maximum is 132.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by the incidence, seriousness and severity of adverse events (AEs).</measure>
    <time_frame>Baseline to 14 weeks</time_frame>
    <description>Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) identified by the Medical Dictionary for Regulatory Activities (MedDRA) preferred term (PT) and grouped by MedDRA System Organ Class (SOC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of laboratory changes.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Incidence of abnormalities or clinically-significant changes from Baseline in laboratory test data (chemistry, hematology, and urinalysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital Sign changes.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Incidence of abnormalities or clinically-significant changes from Baseline in Vital sign measurements (blood pressure as measured in mmHg, heartrate as measured in beats per minute, and temperature as measured in degrees Fahrenheit or Celsius).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Electrocardiogram changes.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Incidence of abnormalities or clinically-significant changes from Baseline in 12-lead electrocardiogram (ECG) QT-interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts 1-4, change from baseline during the on-medication state.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Part I, Non‐Motor Aspects of Experiences of Daily Living (13 items); Part II, Motor Aspects of Experiences of Daily Living (13 items); Part III, Motor Examination (33 items); and Part IV, Motor Complications (6 items). Each Parkinsonian sign or symptom is rated on a 5‐point Likert‐type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The maximum total MDS-UPDRS score is 272, indicating the worst possible disability from Parkinson's Disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Montreal Cognitive Assessment (MoCA), change from baseline in MoCA during the on-medication state.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The Montreal Cognitive Assessment (MoCA) is a neuropsychological tool that requires approximately 15 minutes to assess the following domains: attention, executive function, memory, language, visuoconstructional skills, and orientation. MoCA scores range between 0 and 30, with higher scores indicating more intact cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Schwab and England Activities of Daily Living (SE-ADL) Scale, change from baseline in SE-ADL during the on-medication state.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The SE-ADL evaluates patients' perceptions of global functional capacity and dependence. Scoring is expressed in terms of percentage, in 10 steps from 100 to 0 (100% indicates completely independent, 0% indicates bedridden with impaired vegetative functions), so that the lower the score, the worse the functional status. The assessment is conducted by a trained clinician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Clinical Impression of Severity Index - PD (CISI-PD), change from baseline in CISI-PD during the on-medication state.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The CISI-PD is a severity index formed by four items (motor signs, disability, motor complications, and cognitive status), rated 0 (not at all) to 6 (very severe or completely disabled).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39), change from baseline in PDQ-39 during the on-medication state.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The PDQ-39 is a patient-reported outcome of 39 questions relating to 8 key areas of health and daily activities, including both motor and non-motor symptoms. The eight dimensions include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. It is scored on a scale of 0-100 with lower scores indicating better health and high scores indicating more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Sheehan-Suicidality Tracking Scale (S-STS), change from baseline in S-STS during the on-medication state.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The standard version of the S-STS is a 16-item scale that assesses the seriousness of suicidality phenomena on a Likert-type scale (0-4) ranging from &quot;not at all&quot; (0) to &quot;extremely&quot; (4), where higher scores indicate more risk of suicidality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-meter timed walk.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Change from baseline in a 10-meter timed walk during the on-medication state and the off-medication state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Hauser 3-Day Patient Diary, change from baseline in the Hauser 3-Day Patient Diary during the on-medication state.</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The Hauser Patient Diary was developed to assess functional status over a period of time in patients with motor fluctuations and dyskinesia. The diary is designed to record patient motor state for half-hour intervals over a 24-hour period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>AKST4290</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive AKST4290, 400 mg twice daily, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo, twice daily, for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKST4290</intervention_name>
    <description>Oral AKST4290</description>
    <arm_group_label>AKST4290</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of clinically established or clinically probable PD according to MDS-PD
             criteria with at least 1 year of PD symptoms.

          -  Modified Hoehn and Yahr ≤2.5.

          -  Have notable motor worsening during off-medication state.

          -  Clear-cut improvement of motor response to levodopa medications, as assessed by the
             investigator.

          -  Must be on stable dopaminergic therapy (e.g., levodopa, dopamine agonists, monoamine
             oxidase inhibitors, catechol-O-methyl transferase inhibitors, amantadine), for at
             least 8 weeks prior to enrollment and remain on stable dose during the 12-week
             treatment period.

          -  Female subjects must not be pregnant or breastfeeding. Women of childbearing potential
             (WOCBP) must have a negative pregnancy test at Screening. WOCBP must agree to use
             highly effective contraception prior to study entry. Male subjects must be willing to
             use a barrier method of contraception.

        Key Exclusion Criteria:

          -  Secondary or atypical parkinsonian syndromes, for example, patients with parkinsonism
             from encephalitis, metabolic disorders, vascular parkinsonism, drug-induced
             parkinsonism, multiple system atrophy, corticobasal ganglia degeneration, progressive
             supranuclear palsy, Lewy body dementia.

          -  History of any brain surgery for PD (e.g., pallidotomy, deep brain stimulation, or
             fetal tissue transplant).

          -  Conditions affecting the peripheral or central nervous system, unless related to PD,
             that would affect the ability to adequately perform the MDS-UPDRS and motor
             assessments: i.e., severe sensory neuropathy affecting arm or leg function, or stroke
             affecting motor or gait function.

          -  Significant alcohol or drug abuse within past 2 years.

          -  Based on ECG reading, subjects with a risk of QT prolongation.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alkahest Clinical Trials</last_name>
    <phone>650-801-0474</phone>
    <email>trials@alkahest.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carson Bartley</last_name>
      <phone>404-881-5800</phone>
      <email>abartley@acmr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital West Bloomfield</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Kaminski</last_name>
      <phone>248-661-6540</phone>
      <email>Parkinsons@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Movement Disorder Clinic of Oklahoma PLLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Davis</last_name>
      <phone>918-392-4530</phone>
      <email>bernadette.davis@mdcok.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AS Ida-Tallinna Keskhaigla / East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Astra Kliinik / Astra Team Clinic</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Agatharied GmbH</name>
      <address>
        <city>Hausham</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Weck</last_name>
      <phone>+49 8026 / 393 - 4765</phone>
      <email>Christiane.Weck@khagatharied.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Lorenzl</last_name>
      <email>stefan.lorenzl@khagatharied.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Elena-Klinik Kassel</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Meilick</last_name>
      <phone>+493419724202</phone>
      <email>studienambulanz.neurologie@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UKGM Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Zwirner</last_name>
      <phone>+49 89 4140 8233</phone>
      <email>silke.zwirner@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Nußbaum</last_name>
      <phone>+4970712983734</phone>
      <email>Susanne.Nussbaum@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Kassubek</last_name>
      <phone>+497311771206</phone>
      <email>jan.kassubek@uni-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PRATIA/ Medical Center PRATIA</name>
      <address>
        <city>Częstochowa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii/ Cracow Academy of Neurology</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Zdrowia Dr Boczarska-Jedynak Spolka Z Oraganiczona Odpowiedzialnoscia Spolka Komandytowa/ Institute of Health dr Boczarska-Jedynak</name>
      <address>
        <city>Oświęcim</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicome SP. ZO. O./ Medicome</name>
      <address>
        <city>Oświęcim</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurologiczny Nzoz Centrum Leczenia Sm Osrodek Badan Klinicznych</name>
      <address>
        <city>Plewiska</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Euro-Neuro, s.r.o., Neurologická ambulancia</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnica Kramáre II. Neurologická klinika LF UK a UNB /2nd Dept. Of Neurology, Comenius University Faculty of Medicine and University Hospital Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnica s poliklinikou Sv. Lukáša Galanta, a. s Neurologické oddelenie /Neurology Dpt., NsP Galanta</name>
      <address>
        <city>Galanta</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Martin Neurologická klinika/University hospital Martin, Clinic of Neurology</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Neurocognitive Disorders</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Movement Disorder</keyword>
  <keyword>Shaking Palsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

